Biosynex S.A. Acquires ProciseDx Inc.

June 13, 2023

French diagnostics company Biosynex S.A. has acquired ProciseDx Inc., a U.S.-based point-of-care in vitro diagnostics company. The acquisition will help Biosynex commercialize ProciseDx's therapeutic drug monitoring (TDM) tests for infliximab and adalimumab in the United States and accelerate point-of-care biologic drug monitoring.

Buyers
Biosynex S.A.
Targets
ProciseDx Inc.
Industry
Medical Devices
Location
California, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.